

Anti-Human CD253 (TRAIL) SAFIRE Purified

Catalog Number :25611-25

RUO: For Research Use Only. Not for use in diagnostic procedures.

Product Information

Clone: RIK-2

Format/Conjugate: SAFIRE Purified

Concentration: 1.0 mg/mL

Reactivity: Human

Laser: Not Applicable

Peak Emission: Not Applicable

Peak Excitation: Not Applicable

Filter: Not Applicable

Brightness (1=dim,5=brightest): Not Applicable

Isotype: Mouse IgG1, kappa

Formulation: Phosphate-buffered aqueous solution, pH7.2.

Storage: Product should be kept at 2-8°C.

Applications: FC, FA

Description

The RIK-2 monoclonal antibody recognizes human CD253, otherwise known as the TNF-related apoptosis inducing ligand (TRAIL) or tumor necrosis factor (ligand) superfamily member 10 (TNFSF10). TRAIL is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. The RIK-2 antibody is reported to block cellular apoptosis induced by TRAIL.

Preparation & Storage

The product should be stored undiluted at 4°C. Do not freeze. The monoclonal antibody was purified utilizing affinitychromatography.

Application Notes

The antibody has been analyzed for quality through the flow cytometric analysis of the relevant cell type. It is recommended that the reagent be titrated for optimal performance for each application.

References

- 1.Kayagaki, N., Yamaguchi, N., Nakayama, M., Kawasaki, A., Akiba, H., Okumura, K., Yagita, H. (1999). Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity.;The Journal of Immunology,;162(5), 2639-2647.
2. Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., Ashkenazi, A. (1996). Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.;Journal of Biological Chemistry,271(22), 12687-12690.
3. Kaplan, M. J., Ray, D., Mo, R. R., Yung, R. L., Richardson, B. C. (2000). TRAIL (Apo2 ligand) and TWEAK (Apo3 ligand) mediate CD4+ T cell killing of antigen-presenting macrophages.;The Journal of Immunology,;164(6), 2897-2904.